SCHEMBL3765835

SCHEMBL3765835

Cc1c(N=C=O)cccc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.66
TSHR P16473 1/20 0.45
TLR2 O60603 1/20 0.45
TLR1 Q15399 1/20 0.45
TLR6 Q9Y2C9 1/20 0.45
ALDH1A1 P00352 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
HPGD P15428 4/20 0.44
HSP90AA1 P07900 2/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 4/20 0.43
KDM4E B2RXH2 4/20 0.43
TDP1 Q9NUW8 2/20 0.42
PSMD14 O00487 1/20 0.42
MMP2 P08253 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3125776 0.81 CYP3A4 (0.59) CYP3A4TSHRTLR2TLR1TLR6
SCHEMBL4687669 0.81 ALDH1A1 (0.52) CYP3A4ALDH1A1MEN1KMT2AHPGD
SCHEMBL15092 0.80 CYP3A4 (1.00) CYP3A4TSHRALDH1A1HPGDHSD17B10
SCHEMBL10594316 0.80 CYP3A4 (0.47) CYP3A4TSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL13632546 0.79 TLR2 (0.51) CYP3A4TSHRTLR2TLR1TLR6
Hydrochloric Acid SCHEMBL10392666 0.79 ALDH1A1 (0.50) CYP3A4ALDH1A1MEN1KMT2AHPGD
Methane SCHEMBL5177350 0.79 ALDH1A1 (0.50) CYP3A4ALDH1A1MEN1KMT2AHPGD
SCHEMBL27943596 0.79 CYP3A4 (0.46) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL27946613 0.78 CYP3A4 (0.95) CYP3A4TSHRALDH1A1HPGDTDP1
SCHEMBL5502031 0.78 CYP3A4 (0.46) CYP3A4TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed
WO-2005019193-A2 PHENYLUREA DERIVATIVES USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY POLO-LIKE KINASES (PLK) SMITHKLINE BEECHAM CORPORATION (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 CYP3A4 768/4885TSHR 819/4885TLR2 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.